Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease
Monday, 18 August 2025 ()
On Saturday, the U.S. Food and Drug Administration (FDA) approved an additional indication for Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with…
|
||||
You Might Like |
||||
